ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2018
Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Survival outcomes of surgery for retroperitoneal sarcomas: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Evaluation of RECIST v1.1 for predicting overall survival in sarcoma patients with pulmonary metastasis.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Primary sclerosing epithelioid fibrosarcoma of the iliac fossa: a case report.Frontiers in oncology · 2026Article
- The Two-Decade Experience of Oncovascular Reconstruction in Patients with Retroperitoneal Sarcoma.Annals of vascular surgery · 2025Article
- Global trends in retroperitoneal sarcomas surgery: a bibliometric analysis from 2005 to 2024.Discover oncology · 2025Article
- Construction and Verification of a Predictive Nomogram for Overall Survival in Patients with Large Retroperitoneal Liposarcoma: A Population-Based Cohort Study.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Multiple surgical interventions improve survival in locally recurrent retroperitoneal sarcoma: a retrospective cohort analysis.Frontiers in oncology · 2025Article
- The independent prognostic nomogram models for primary and recurrent retroperitoneal liposarcoma: a population-based cohort study.Frontiers in medicine · 2025Article
- Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations.Cancers · 2024Review
- Predictors and outcomes of recurrent retroperitoneal liposarcoma: new insights into its recurrence patterns.BMC cancer · 2023Article
- Review
- A competing risk-based nomogram to predict cancer-specific survival in patients with retroperitoneal leiomyosarcoma.Heliyon · 2023Article
- Article
- The Role of Surgery in Oligometastatic Retroperitoneal Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- Article
- Predictors and outcomes of recurrent retroperitoneal liposarcoma with multiple tumors.Frontiers in medicine · 2023Article
- Intra and extra pelvic multidisciplinary surgical approach of retroperitoneal sarcoma: Case series report.World journal of clinical cases · 2022Article
- Prediction of intraoperative bleeding and blood transfusion in patients with recurrent retroperitoneal liposarcoma: a retrospective study.Annals of translational medicine · 2022Article
- Survival and prognostic factors in patients undergoing pulmonary metastasectomy for lung metastases from retroperitoneal sarcoma.World journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Introduction: Retroperitoneal sarcoma (RPS) is a rare disease accounting for 0.1%-0.2% of all malignancies. Management of RPS is complex and requires multidisciplinary, tailored treatment strategies at all stages, but especially in the context of metastatic or multifocal recurrent disease. Due to the rarity and heterogeneity of this family of diseases, the literature to guide management is limited. Methods: The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG) is an international collaboration of sarcoma experts from all disciplines convened in an effort to overcome these limitations. The TARPSWG has compiled the available evidence surrounding metastatic and multifocally recurrent RPS along with expert opinion in an iterative process to generate a consensus document regarding the complex management of this disease. The objective of this document is to guide sarcoma specialists from all disciplines in the diagnosis and treatment of multifocal recurrent or metastatic RPS. Results: All aspects of patient assessment, diagnostic processes, local and systemic treatments, and palliation are reviewed in this document, and consensus recommendations provided accordingly. Recommendations were guided by available evidence, in conjunction with expert opinion where evidence was lacking. Conclusions: This consensus document combines the available literature regarding the management of multifocally recurrent or metastastic RPS with the practical expertise of high-volume sarcoma centers from multiple countries. It is designed as a tool for decision making in the complex multidisciplinary management of this condition and is expected to standardize management across centers, thereby ensuring that patients receive the highest quality care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.